TY - T1的逆转慢性偏头痛患者的情景与Fremanezumab治疗偏头痛的分类(P4.112) JF -神经学乔-神经学六世- 90 - 15补充SP - P4.112盟约书亚·m·科恩AU -克里斯汀Bibeau盟Maja冷冻AU -迈克尔·j·Seminerio盟Vere首页na拉米雷斯Campos AU -辛格Rashmi b . Halker盟杰西卡Ailani Y1 - 2018/04/10 UR - //www.ez-admanager.com/content/90/15_Supplement/P4.112.abstract N2 -目的:评价Fremanezumab对降级的影响从慢性偏头痛(CM)、情景性偏头痛(EM)。背景:厘米和EM临床、功能和结构上有区别,证据表明他们可能是独立的条件。此外,患者CM通常并存状况有更多和更频繁的药物过度使用,这使他们的临床管理。Fremanezumab (tev - 48125),一个全人源化单克隆抗体针对降钙素相关基因肽(CGRP怎样),展示了在偏头痛的预防功效。设计/方法:在这第三阶段,多中心、随机、双盲、安慰剂对照,与这些相应平行的组织学习,成年人与前瞻性证实厘米(≥15天头痛和偏头痛≥8天/月)被随机分配比皮下注射fremanezumab季度(675毫克基线;安慰剂在周4和8),每月fremanezumab(675毫克基线;在周4和8)225毫克,或匹配的安慰剂在12周的治疗期。事后分析评估病人恢复的比例从CM EM,定义为患者头痛≥15天/月在基线(28天预处理段),然后& lt;每月15天头痛在所有三个月的治疗期。结果:1130厘米的分析患者随机在这个试验(季度,N = 376;每月,N = 379;安慰剂,N = 375),更多fremanezumab-treated病人恢复每月从头痛≥15天在基线& lt;几个月每月15天头痛1,2,3(季度:121例(32%);月:133例[35%])比那些接受安慰剂(86名患者(23%); both, P≤0.002). On average, these fremanezumab-treated patients had 18–19 headache days per month at baseline and showed reductions to 6–9 headache days during any month in the treatment period, representing up to an approximately 70% reduction in headache days.Conclusions: Along with its efficacy as a migraine preventive treatment, fremanezumab demonstrated the potential benefit for reversion from CM to EM.Study Supported by:This study was funded by Teva Pharmaceutical Industries, Petach Tikva, Israel.Disclosure: Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Bibeau has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries. Dr. Galic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Seminerio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Ramirez Campos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Halker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, MedLink. Dr. Halker has received personal compensation in an editorial capacity for Current Neurology and Neuroscience Reports. Dr. Ailani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Avanir, Eli Lilly, Teva Pharmaceuticals, Promius. Dr. Ailani has received personal compensation in an editorial capacity for Current Pain and Headache Reports. Dr. Ailani has received research support from Theranica. ER -